Skip to main content
Premium Trial:

Request an Annual Quote

Investment Bank Downgrades Cepheid Stock; Shares Slide 3.8 Percent

NEW YORK (GenomeWeb News) — Investment bank Caris & Company today downgraded Cepheid’s stock rating to “Above Average” from “Buy.”
 
Shares in the company were down 3.75 percent, or $.70, at $17.98 in mid-afternoon trading.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.